AUTL
Price:
$4.005
Market Cap:
$1.07B
Autolus Therapeutics plc, a clinical-stage biopharmaceutical company, develops T cell therapies for the treatment of cancer. The company's clinical-stage programs include obecabtagene autoleucel (AUTO1), a CD19-targeting programmed T cell investigational therapy that is in Phase 1b/2 clinical trial for the treatment of adult ALL; AUTO1/22, which is in a Phase 1 clinical trial in pediatric patients with relapsed or refractory ALL; AUTO4, a programmed T cell investigational therapy for the treatment of peripheral T-cell lymphoma targeting TRBC1; AUTO6NG, a programmed T cell investigational therapy, which is in preclinical trail targeting GD2 in development for the treatment of neuroblastoma; a...[Read more]
Industry
Biotechnology
IPO Date
2018-06-22
Stock Exchange
NASDAQ
Ticker
AUTL
According to Autolus Therapeutics plc’s latest financial reports and current stock price. The company's current Enterprise Value is 647.24M. This represents a change of 6.87% compared to the average of 605.66M of the last 4 quarters.
The mean historical Enterprise Value of Autolus Therapeutics plc over the last ten years is 358.14M. The current 647.24M Enterprise Value has changed 17.97% with respect to the historical average. Over the past ten years (40 quarters), AUTL's Enterprise Value was at its highest in in the December 2018 quarter at 1.07B. The Enterprise Value was at its lowest in in the December 2022 quarter at -135541306.00.
Average
358.14M
Median
334.40M
Minimum
-177692540.00
Maximum
933.59M
Discovering the peaks and valleys of Autolus Therapeutics plc Enterprise Value, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.
Maximum Annual Increase = 274.36%
Maximum Annual Enterprise Value = 933.59M
Minimum Annual Increase = -625.39%
Minimum Annual Enterprise Value = -177692540.00
Year | Enterprise Value | Change |
---|---|---|
2023 | 933.59M | -625.39% |
2022 | -177692540.00 | -309.60% |
2021 | 84.78M | -76.57% |
2020 | 361.79M | -5.79% |
2019 | 384.04M | -50.63% |
2018 | 777.83M | 274.36% |
2017 | 207.78M | -34.40% |
2016 | 316.71M | -5.29% |
The current Enterprise Value of Autolus Therapeutics plc (AUTL) is greater than its 3-year, greater than its 5-year, and greater than its 10-year historical averages
3-year avg
280.22M
5-year avg
317.30M
10-year avg
358.14M
Autolus Therapeutics plc’s Enterprise Value is less than Cullinan Oncology, Inc. (930.13M), greater than Bolt Biotherapeutics, Inc. (37.47M), less than Day One Biopharmaceuticals, Inc. (1.01B), greater than Lyra Therapeutics, Inc. (22.69M), greater than Acumen Pharmaceuticals, Inc. (93.64M), greater than X4 Pharmaceuticals, Inc. (40.79M), greater than Inozyme Pharma, Inc. (343.89M), less than VectivBio Holding AG (848.58M), greater than Terns Pharmaceuticals, Inc. (458.36M), greater than Amylyx Pharmaceuticals, Inc. (89.50M), greater than Ikena Oncology, Inc. (46.38M), greater than Anebulo Pharmaceuticals, Inc. (41.53M), greater than Celcuity Inc. (623.73M), greater than MediciNova, Inc. (59.15M), greater than Rezolute, Inc. (237.24M), less than Mirati Therapeutics, Inc. (3.91B), less than Apellis Pharmaceuticals, Inc. (5.11B),
Company | Enterprise Value | Market cap |
---|---|---|
930.13M | $1.04B | |
37.47M | $24.78M | |
1.01B | $1.25B | |
22.69M | $17.85M | |
93.64M | $133.38M | |
40.79M | $109.78M | |
343.89M | $312.42M | |
848.58M | $1.06B | |
458.36M | $549.60M | |
89.50M | $161.36M | |
46.38M | $81.56M | |
41.53M | $46.68M | |
623.73M | $557.67M | |
59.15M | $103.00M | |
237.24M | $240.80M | |
3.91B | $4.12B | |
5.11B | $5.00B |
One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like Autolus Therapeutics plc using the financials and key metrics that matter to you in a single view.
The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:
Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.
Get your free trial here.
The easiest way to analyze a company like Autolus Therapeutics plc or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.
Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.
Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.
What is the Enterprise Value?
How can you use the Enterprise Value?
What is Autolus Therapeutics plc's Enterprise Value?
What is the highest Enterprise Value for Autolus Therapeutics plc (AUTL)?
What is the 3-year average Enterprise Value for Autolus Therapeutics plc (AUTL)?
What is the 5-year average Enterprise Value for Autolus Therapeutics plc (AUTL)?
How does the current Enterprise Value for Autolus Therapeutics plc (AUTL) compare to its historical average?